Form 8-K - Current report:
SEC Accession No. 0001213900-23-075179
Filing Date
2023-09-08
Accepted
2023-09-08 08:40:39
Documents
14
Period of Report
2023-09-08
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea184839-8k_citius.htm   iXBRL 8-K 24559
2 PRESS RELEASE ea184839-8kex99i_citius.htm EX-99.1 13256
6 GRAPHIC image_001.jpg GRAPHIC 4478
  Complete submission text file 0001213900-23-075179.txt   222606

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ctxr-20230908.xsd EX-101.SCH 3027
4 XBRL LABEL FILE ctxr-20230908_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE ctxr-20230908_pre.xml EX-101.PRE 22367
8 EXTRACTED XBRL INSTANCE DOCUMENT ea184839-8k_citius_htm.xml XML 3309
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 231243737
SIC: 2834 Pharmaceutical Preparations